Celebrating Diversity Within the Sickle Cell Community: Commitment, Innovation, Practice
avatar for Mark Dewitt

Mark Dewitt

Berkeley University
Project Scientist
"Mark DeWitt is project manager for a late-stage preclinical development project in sickle cell disease, funded through a grant from the California Institute for Regenerative Medicine (CIRM). The project is a collaboration between UCLA, UC Berkeley, and UC San Francisco. Our approach is to obtain autologous HSC by mobilization and apheresis of a sickle cell disease patient, correct the causative mutation in the ß-globin gene (HBB) using CRISPR/Cas9 ex vivo by electroporation with a mix of non-viral gene editing reagents, and re-infuse the product into the patient. The safety and feasibility of this approach will be assessed through a Phase I clinical trial, likely in 2019."